8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 28, 2007

NATROL, INC.
(Exact name of registrant as specified in its charter)
Delaware	0-24567	95-3560780
(State or other Jurisdiction of	(Commission File Number)	(IRS Employer
Incorporation)		Identification No.)
21411 Prairie Street
Chatsworth, California 91311
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (818) 739-6000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Copy to: Clifford E. Neimeth, Esq. Greenberg Traurig, LLP The MetLife Building 200 Park Avenue New York, NY 10166 (212) 801-9200

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

c	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
c	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240. 14a-12)
c	Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
c	Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.01. Completion of Acquisition or Disposition of Assets.

     The information set forth in Item 5.01 of this Current Report on Form 8-K is incorporated into this Item 2.01 in its entirety by reference.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.

      The information set forth in Item 5.01 of this Current Report on Form 8-K is incorporated into this Item 3.01 in its entirety by reference.

     As a result of the Merger (as defined below), Natrol, Inc. (the “Company”) no longer fulfills the numerical listing requirements of the NASDAQ Global Market (“Nasdaq”). Accordingly, the Company has requested that the Company’s common stock, $0.01 par value (the “Common Stock”), be withdrawn from listing on Nasdaq as of the close of business on December 28, 2007. Nasdaq has advised the Company that it will file with the Securities and Exchange Commission (the “SEC”) a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to effect the delisting of the Common Stock from Nasdaq and the deregistration of the Common Stock under the Exchange Act. The Company will also file with the SEC a Certification on Form 15 under the Exchange Act to suspend the Company’s reporting obligations under Sections 13(a) and 15(d) of the Exchange Act.

Item 5.01. Changes in Control of Registrant.

     As previously announced, on November 18, 2007, the Company entered into an Agreement and Plan of Merger dated as of November 18, 2007 (the “Merger Agreement”) with Plethico Pharmaceuticals Limited, a public limited company incorporated under the laws of India (“Parent”), and Nutra Acquisition Company, Inc., a Delaware corporation and an indirect subsidiary of Parent (“Purchaser”), providing for the merger of Purchaser with and into the Company.

     Pursuant to the Merger Agreement, on November 27, 2007, Purchaser commenced a tender offer (the “Offer”) to purchase all of the Company’s outstanding shares of Common Stock at a purchase price of $4.40 per share, net to the seller in cash (the “Offer Price”), without interest and less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 27, 2007 and in the related Letter of Transmittal furnished to the holders of Common Stock.

     The Offer expired by its terms and was successfully completed at 5:00 p.m., New York City time, on Thursday, December 27, 2007. Upon expiration of the Offer, Purchaser accepted for payment in accordance with the terms of the Offer all shares of Common Stock that were validly tendered and not withdrawn prior to expiration of the Offer, and payment for such shares will be made promptly, in accordance with the terms of the Offer and as required by applicable law. Purchaser has advised the Company that, based upon information obtained by Purchaser from the depositary for the Offer, as of the expiration of the Offer, a total of 13,108,619 shares of Common Stock, which in the aggregate represented approximately 91.9% of the then outstanding shares of Common Stock, were validly tendered and not withdrawn prior to the expiration of the Offer,

and an additional 63,245 shares of Common Stock were tendered by notice of guaranteed delivery.

     On December 27, 2007, Plethico assigned all of its interest in Purchaser to M/s Plethico Global Holdings B.V., a subsidiary of Parent (“Plethico Global”). The business address of Plethico Global is Hobbarmastraat 14, 1071 ZB, Amsterdam, The Netherlands. As a result of such assignment, Purchaser became a direct wholly owned subsidiary of Plethico Global. Plethico Global is organized under the laws of The Netherlands.

     Following the acceptance for payment by Purchaser of shares of Common Stock pursuant to the Offer, on December 28, 2007 (the “Effective Time”), the acquisition of the Company by Parent was completed by means of a “short-form” merger of Purchaser with and into the Company (the “Merger”), with the Company continuing its corporate existence under the name “Natrol, Inc.” as the surviving corporation (the “Surviving Corporation”) and a wholly owned subsidiary of Plethico Global, in accordance with applicable provisions of Delaware law that authorize the completion of such a merger without a vote of the Company’s stockholders.

     In the Merger, at the Effective Time, each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than shares of Common Stock owned by the Company or any direct or indirect subsidiary of the Company and except for shares of Common Stock owned by Parent, Purchaser, or any subsidiary of Parent or Purchaser or held in the treasury of the Company), was canceled and converted into the right to receive the Offer Price, without interest and less any applicable withholding taxes, subject to the rights of holders thereof to seek appraisal of the “fair value” of their shares of Common Stock by following the procedures required by Section 262 of the Delaware General Corporation Law. The amount of consideration and source of funds used by the Purchaser to acquire the Company’s outstanding shares of Common Stock is described in Item 7 of the Purchaser’s Schedule TO and related Offer to Purchase, dated November 27, 2007, as amended, which description is incorporated herein by reference.

     The information set forth in Item 5.02 of this Current Report on Form 8-K is incorporated into this Item 5.01 in its entirety by reference.

     The foregoing description of the Merger Agreement and related transactions does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed by the Company with the SEC on November 20, 2007 and is incorporated into this Item 5.01 in its entirety by reference.

     The other information required by Item 5.01(a) of Form 8-K is contained in (i) the Company’s Solicitation/Recommendation Statement on Schedule 14D-9, originally filed with the SEC on November 27, 2007, as subsequently amended (the “Statement”), and (ii) the Tender Offer Statement on Schedule TO, originally filed by Purchaser and Parent with the SEC on November 27, 2007, as subsequently amended (the “Schedule TO”), and such information is incorporated in this Item 5.01 in its entirety by reference.

     On December 28, 2007, Parent issued a press release announcing the expiration of the Offer and the results thereof, that it had accepted for payment in accordance with the terms of the Offer all shares of Common Stock that were validly tendered and not withdrawn prior to the expiration of the Offer and that it had completed the Merger. On December 28, 2007, the Company also issued a press release regarding the foregoing. A copy of each such press release is filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and is incorporated in this Item 5.01 in its entirety by reference.

Item 5.02.	Departure of Directors or Certain Officers; Election of Directors;
	Appointment of Certain Officers; Compensatory Arrangements of Certain
	Officers.

     Pursuant to the Merger Agreement, at the Effective Time, the directors and officers of Purchaser immediately prior thereto became the directors and officers, respectively, of the Surviving Corporation, in each case until their successors are duly elected or appointed and qualified. The information regarding the new directors of the Surviving Corporation (Shashikant Patel, Rajiv Bedi, Hemant Modi, Sanjay Pai and Manmohan A. Patel) set forth in the Offer to Purchase, dated November 27, 2007, as amended, attached as Schedule A to the Schedule TO, and in the Section 14(f) Information Statement of the Company attached as Annex B to the Statement, as amended, is incorporated in this Item 5.02 in its entirety by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     Pursuant to the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation was amended and restated in its entirety to be identical to the certificate of incorporation of Purchaser, as in effect immediately prior to the Effective Time (except that the name of the Surviving Corporation set forth therein is “Natrol, Inc.”), and such amended and restated certificate of incorporation became the certificate of incorporation of the Surviving Corporation.

      Pursuant to the Merger Agreement, at the Effective Time, the bylaws of Purchaser, as in effect immediately prior to the Effective Time, became the bylaws of the Surviving Corporation. Following the Merger, the bylaws of the Surviving Corporation will be amended to provide that the name of the Surviving Corporation set forth therein is “Natrol, Inc.”

Item 8.01. Other Events.

     On December 28, 2007, Parent issued a press release announcing the expiration of the Offer and the results thereof, that it had accepted for payment in accordance with the terms of the Offer all shares of Common Stock that were validly tendered and not withdrawn prior to the expiration of the Offer and that it had completed the Merger. On December 28, 2007, the Company also issued a press release regarding the foregoing. A copy of each such press release is filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and is incorporated in this Item 8.01 in its entirety by reference.

Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits:

Exhibit No.	Description
20.1	Solicitation/Recommendation Statement on Schedule 14D-9 of Natrol, Inc. (incorporated by reference in its entirety as originally filed with the SEC on November 27, 2007, as amended).
20.2	Section 14(f) Information Statement of Natrol, Inc. (incorporated by reference in its entirety to Annex B of the Solicitation/Recommendation Statement on

	Schedule 14D-9 of Natrol, Inc. as originally filed with the SEC on November 27, 2007)
20.3	Tender Offer Statement on Schedule TO of Plethico Pharmaceuticals Limited and Nutra Acquisition Company, Inc. (incorporated by reference in its entirety as originally filed with the SEC on November 27, 2007, as amended)
99.1	Press Release of Plethico Pharmaceuticals Limited dated December 28, 2007 (incorporated by reference to Exhibit (a)(1)(J) to the Schedule TO).
99.2	Press Release of Natrol, Inc. dated December 28, 2007.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NATROL, INC.
Date: December 28, 2007	By:	/s/ Dennis Jolicoeur
	Name:	Dennis Jolicoeur
	Title:	Executive Vice President, Chief
		Financial Officer and Treasurer

Exhibit Index

Exhibit No.	Description
99.2	Press Release of Natrol, Inc. dated December 28, 2007.

EX-99.2

Plethico Pharmaceuticals Limited Completes $80.8 Million Acquisition of Natrol, Inc.

FOR IMMEDIATE RELEASE:

CHATSWORTH, CA. -- December 28, 2007 -- Natrol, Inc. (Nasdaq: NTOL), a leading manufacturer and marketer of nationally branded nutritional products, announced today that Nutra Acquisition Company, Inc., an indirect subsidiary of Plethico Pharmaceuticals Limited, a public limited company incorporated under the laws of India, has successfully completed its cash tender offer for outstanding shares of Natrol’s common stock at $4.40 net per share in cash.

On November 18, 2007, Natrol entered into a merger agreement with Plethico and Nutra Acquisition providing for Plethico’s two-step acquisition of Natrol. Pursuant to the merger agreement, on November 27, 2007 Nutra Acquisition commenced a cash tender offer to purchase all outstanding shares of Natrol’s common stock at $4.40 net per share.

The tender offer expired by its terms and was successfully completed at 5:00 p.m., New York City time, on Thursday, December 27, 2007. Nutra Acquisition has accepted for payment all shares of common stock that were validly tendered and not withdrawn prior to expiration of the tender offer, and the cash payment for such shares will be made promptly.

Based upon information obtained from the depositary for the tender offer, as of yesterday at 5:00 p.m., New York City time, a total of 13,108,619 shares of common stock, which in the aggregate represented approximately 91.9% of Natrol’s then outstanding shares of common stock, were validly tendered and not withdrawn in the tender offer, and an additional 63,245 shares were tendered by notice of guaranteed delivery.

Nutra Acquisition successfully acquired in the tender offer a sufficient number of Natrol shares to enable Plethico to effect a so-called “short-form” merger of Nutra Acquisition into Natrol under Delaware law, without any vote or other action by those Natrol stockholders who elected not to participate in the tender offer. As a result of the merger, all outstanding shares of Natrol common stock (not tendered and purchased in the tender offer) were converted into the right to receive $4.40 per share in cash, without interest thereon and less any required withholding taxes, subject to the rights of holders thereof to demand appraisal of the “fair value” of their shares of common stock under applicable Delaware law. December 28, 2007 has been established as the record date under applicable Delaware law for all holders of record of Natrol’s common stock who desire to demand appraisal of the “fair value” of their shares. An information statement and other materials, including a copy of the complete text of Delaware's appraisal statute and a description of the procedures to validly demand and perfect appraisal rights will be disseminated promptly to all such holders.

As a further result of the merger, Natrol has become an indirect subsidiary of Plethico, Natrol’s common stock no longer will be listed and traded on the Nasdaq Global Market and Natrol no longer will be required to file periodic reports and other information with the Securities and Exchange Commission.

Morgan Joseph & Co. Inc. served as financial advisor to Natrol and international law firm, Greenberg Traurig, LLP, acted as Natrol’s public M&A counsel.

About Natrol -- Nourishing the Potential of Mind and Body (SM)

Natrol, Inc. (Nasdaq: NTOL), headquartered in Chatsworth, CA, has a portfolio of health and wellness brands representing quality nutritional supplements, functional herbal teas, and sports nutrition products. Established in 1980, Natrol’s portfolio of brands includes: Natrol®, MRI, Prolab®, Laci Le Beau®, Promensil®, Trinovin®, Nu Hair® and Shen Min®. The company also manufactures supplements for its own brands and on behalf of third parties.

Natrol distributes products nationally through more than 54,000 retailers, as well as internationally in over 40 other countries through distribution partners and subsidiaries in the UK and Hong Kong. Natrol’s dedication to quality is evidenced by its commitment to high manufacturing standards, earning the company an “A” rating from the Natural Products Association’s Good Manufacturing Practices (“GMP”) Certification Program -- a designation achieved by less than ten percent of U.S. nutrition companies. For more information, visit www.Natrol.com.

About Plethico Pharmaceuticals Limited

Plethico Pharmaceuticals Limited (BSE: 532739.BO: PLETHICO), a herbal/nutraceutical focused Indian company, engages in the manufacture, marketing and distribution of pharmaceutical and allied healthcare products in India and internationally. The company’s product portfolio includes: herbal health care products, such as Travisil® and Mountain Herbz® food supplements; consumer healthcare products and neutraceuticals, which include sports nutrition (Coach’s Formula®), confectionary (Byte®, Actifresh®), pharma/OTC (Effertabs®, Therasil®) and pharmaceutical formulations. The Company today operates in Commonwealth of Independent States (CIS), Africa, South East Asia, Latin America and certain gulf countries. Plethico was founded in 1991 and has its Registered office in Indore (Madhya Pradesh) and has its corporate office in Mumbai, India.

Forward-looking statements

The statements made in this press release which are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. As a result of a number of factors, our actual results could differ materially from those set forth in the forward-looking statements. Certain factors that might cause our actual results to differ materially from those in the forward-looking statements include, without limitation those factors set forth under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2006, and in our other filings with the SEC. Natrol is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Contact:
Natrol, Inc.	ICR (Investor Relations)
Wayne M. Bos, 818-739-6000	James Palczynski, 203-682-8229

2